The challenge of emerging SARS-CoV-2 mutants to vaccine development
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The challenge of emerging SARS-CoV-2 mutants to vaccine development
Authors
Keywords
-
Journal
Journal of Genetics and Genomics
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-04-21
DOI
10.1016/j.jgg.2021.03.001
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
- (2021) Lewis F. Buss et al. SCIENCE
- Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021
- (2021) Summer E. Galloway et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
- (2021) Emma C. Thomson et al. CELL
- Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera
- (2021) Daming Zhou et al. CELL
- SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
- (2021) Xiaoying Shen et al. Cell Host & Microbe
- Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques
- (2021) Rong Li et al. Cellular & Molecular Immunology
- Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2
- (2021) Saman Saadat et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Emergence of a Novel SARS-CoV-2 Variant in Southern California
- (2021) Wenjuan Zhang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
- (2021) Merryn Voysey et al. LANCET
- Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
- (2021) Dami A. Collier et al. NATURE
- mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
- (2021) Zijun Wang et al. NATURE
- Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
- (2021) Rita E. Chen et al. NATURE MEDICINE
- SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
- (2021) Constantinos Kurt Wibmer et al. NATURE MEDICINE
- Neutralizing Activity of BNT162b2-Elicited Serum
- (2021) Yang Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
- (2021) Alexander Muik et al. SCIENCE
- Covid-19: The E484K mutation and the risks it poses
- (2021) Jacqui Wise BMJ-British Medical Journal
- The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
- (2020) Qianqian Li et al. CELL
- Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
- (2020) Bette Korber et al. CELL
- Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
- (2020) Xiancai Ma et al. IMMUNITY
- A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs
- (2008) Fu Shi Quan et al. VACCINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now